A model of placebo response in antidepressant clinical trials

American Journal of Psychiatry

Volumn 170, Issue 7, 2013, Pages 723-733

  Rutherford, Bret R ^a   Roose, Steven P ^a  

^a Columbia University College of Physicians and Surgeons New York State Psychiatric Institute ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; PLACEBO;

BIOLOGICAL MODEL; CLINICAL EVALUATION; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); CONCEPTUAL FRAMEWORK; COST EFFECTIVENESS ANALYSIS; DISEASE ACTIVITY; DRUG EFFICACY; DRUG MARKETING; EFFECT SIZE; EXPECTANCY; HEALTH CARE ACCESS; HUMAN; MAJOR DEPRESSION; MASS COMMUNICATION; MENTAL HEALTH CARE; PATIENT ATTITUDE; PHYSICAL DISABILITY; PLACEBO EFFECT; PRIORITY JOURNAL; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SOCIAL ISOLATION; SYMPTOMATOLOGY; SYSTEMATIC ERROR; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE;

EID: 84883203780     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2012.12040474     Document Type: Review

References (67)

1. Walsh BT, Seidman SN, Sysko R, Gould M: Placebo response in studies of major depression: variable, substantial, and growing. JAMA 2002; 287: 1840-1847
2. Bridge JA, Birmaher B, Iyengar S, Barbe RP, Brent DA: Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder. Am J Psychiatry 2009; 166: 42-49
3. Khan A, Bhat A, Kolts R, Thase ME, Brown W: Why has the antidepressant-placebo difference in antidepressant clinical trials diminished over the past three decades? CNS Neurosci Ther 2010; 16: 217-226
4. Khan A, Khan S, Brown WA: Are placebo controls necessary to test new antidepressants and anxiolytics? Int J Neuropsychopharmacol 2002; 5: 193-197
5. Hooper M, Amsterdam JD: Do clinical trials reflect drug potential? A review of FDA evaluation of new antidepressants, in 39th Annual Meeting Abstracts of Poster Presentations, New Clinical Drug Evaluation Unit Program, 1999
6. Nutt D, Goodwin G: ECNP Summit on the future of CNS drug research in Europe 2011: report prepared for ECNP by David Nutt and Guy Goodwin. Eur Neuropsychopharmacol 2011; 21: 495-499
7. Cressey D: Psychopharmacology in crisis. Nature, Jun, 14, 2011 (http://www.nature.com/news/2011/110614/full/news.2011.367. html)
8. World Health Organization: The World Health Report 2004: Changing History, Annex Table 3: Burden of Disease in DALYs by Cause, Sex, and Mortality Stratum in WHO Regions, Estimates for 2002. Geneva, WHO, 2004
9. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M: Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163: 1905-1917
10. Kirsch I, Sapirstein G: Listening to Prozac but hearing placebo: a meta-analysis of antidepressant medication. Prev Treat 1998 (doi: 10.1037/1522-3736.1.1.12a)
11. Khan A, Redding N, Brown WA: The persistence of the placebo response in antidepressant clinical trials. J Psychiatr Res 2008; 42: 791-796
12. Stewart-Williams S, Podd J: The placebo effect: dissolving the expectancy versus conditioning debate. Psychol Bull 2004; 130: 324-340
13. Khan A, Kolts RL, Thase ME, Krishnan KR, Brown W: Research design features and patient characteristics associated with the outcome of antidepressant clinical trials. Am J Psychiatry 2004; 161: 2045-2049
14. Rutherford BR, Sneed JR, Roose SP: Does study design influence outcome? The effects of placebo control and treatment duration in antidepressant trials. Psychother Psychosom2009; 78: 172-181
15. Sneed JR, Rutherford BR, Rindskopf D, Lane DT, Sackeim HA, Roose SP: Design makes a difference: a meta-analysis of antidepressant response rates in placebo-controlled versus comparator trials in late-life depression. Am J Geriatr Psychiatry 2008; 16: 65-73
16. Papakostas GI, Fava M: Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol 2009; 19: 34-40
17. Sinyor M, Levitt AJ, Cheung AH, Schaffer A, Kiss A, Dowlati Y, Lanctôt KL: Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses. J Clin Psychiatry 2010; 71: 270-279
18. Meyer B, Pilkonis PA, Krupnick JL, Egan MK, Simmens SJ, Sotsky SM: Treatment expectancies, patient alliance, and outcome: further analyses from the National Institute of Mental Health Treatment of Depression Collaborative Research Program. J Consult Clin Psychol 2002; 70: 1051-1055
19. Krell HV, Leuchter AF, Morgan M, Cook IA, Abrams M: Subject expectations of treatment effectiveness and outcome of treatment with an experimental antidepressant. J Clin Psychiatry 2004; 65: 1174-1179
20. Rutherford BR, Marcus SM, Wang P, Sneed JR, Pelton G, Devanand D, Duan N, Roose SP: A randomized, prospective pilot study of patient expectancy and antidepressant outcome. Psychol Med (Epub ahead of print, Sept 13, 2012)
21. Rutherford BR, Sneed JR, Tandler JM, Rindskopf D, Peterson BS, Roose SP: Deconstructing pediatric depression trials: an analysis of the effects of expectancy and therapeutic contact. J Am Acad Child Adolesc Psychiatry 2011; 50: 782-795
22. Di Blasi Z, Kleijnen J: Context effects: powerful therapies or methodological bias? Eval Health Prof 2003; 26: 166-179
23. Bass MJ, Buck C, Turner L, Dickie G, Pratt G, Robinson HC: The physician's actions and the outcome of illness in family practice. J Fam Pract 1986; 23: 43-47
24. Benedetti F: Mechanisms of placebo and placebo-related effects across diseases and treatments. Annu Rev Pharmacol Toxicol 2008; 48: 33-60
25. Posternak MA, Zimmerman M: Therapeutic effect of follow-up assessments on antidepressant and placebo response rates in antidepressant efficacy trials: meta-analysis. Br J Psychiatry 2007; 190: 287-292
26. Mojtabai R, Olfson M: National patterns in antidepressant treatment by psychiatrists and general medical providers: results from the National Comorbidity Survey Replication. J Clin Psychiatry 2008; 69: 1064-1074
27. Stettin GD, Yao J, Verbrugge RR, Aubert RE: Frequency of followup care for adult and pediatric patients during initiation of antidepressant therapy. Am J Manag Care 2006; 12: 453-461
28. Morrato EH, Libby AM, Orton HD, Degruy FV 3rd, Brent DA, Allen R, Valuck RJ: Frequency of provider contact after FDA advisory on risk of pediatric suicidality with SSRIs. Am J Psychiatry 2008; 165: 42-50
29. Stein DJ, Baldwin DS, Dolberg OT, Despiegel N, Bandelow B: Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram. J Clin Psychiatry 2006; 67: 1741-1746
30. Trivedi MH, Rush H: Does a placebo run-in or a placebo treatment cell affect the efficacy of antidepressant medications? Neuropsychopharmacology 1994; 11: 33-43
31. Faries DE, Heiligenstein JH, Tollefson GD, Potter WZ: The doubleblind variable placebo lead-in period: results from two antidepressant clinical trials. J Clin Psychopharmacol 2001; 21: 561-568
32. Barnett AG, van der Pols JC, Dobson AJ: Regression to the mean: what it is and how to deal with it. Int J Epidemiol 2005; 34: 215-220
33. Marcus SM, Gorman JM, Tu X, Gibbons RD, Barlow DH, Woods SW, Shear MK: Rater bias in a blinded randomized placebocontrolled psychiatry trial. Stat Med 2006; 25: 2762-2770
34. Rief W, Nestoriuc Y, Weiss S, Welzel E, Barsky AJ, Hofmann SG: Meta-analysis of the placebo response in antidepressant trials. J Affect Disord 2009; 118: 1-8
35. Lambert MJ, Hatch DR, Kingston MD, Edwards BC: Zung, Beck, and Hamilton rating scales as measures of treatment outcome: a meta-analytic comparison. J Consult Clin Psychol 1986; 54: 54-59
36. Landin R, DeBrota DJ, DeVries TA, Potter WZ, Demitrack MA: The impact of restrictive entry criterion during the placebo lead-in period. Biometrics 2000; 56: 271-278
37. Mundt JC, Greist JH, Jefferson JW, Katzelnick DJ, DeBrota DJ, Chappell PB, Modell JG: Is it easier to find what you are looking for if you think you know what it looks like? J Clin Psychopharmacol 2007; 27: 121-125
38. Greenberg RP, Bornstein RF, Greenberg MD, Fisher S: A metaanalysis of antidepressant outcome under "blinder" conditions. J Consult Clin Psychol 1992; 60: 664-669, discussion 670-677
39. DeBrota DJ, Demitrack MA, Landin R, Kobak KA, Greist JH, Potter W: A comparison between interactive voice response system-administered HAM-D and clinician-administered HAM-D in patients with major depressive episode, in 39th Annual Meeting Abstracts of Poster Presentations, New Clinical Drug Evaluation Unit Program, 1999
40. Paulhus DL: Measurement and control of response bias, in Measures of Personality and Social Psychological Attitudes. Edited by Robinson JP, Shaver PR, Wrightsman LS. San Diego, Academic Press, 1991, pp 17-59
41. Mulsant BH, Kastango KB, Rosen J, Stone RA, Mazumdar S, Pollock BG: Interrater reliability in clinical trials of depressive disorders. Am J Psychiatry 2002; 159: 1598-1600
42. Kobak KA, Kane JM, Thase ME, Nierenberg AA: Why do clinical trials fail? The problem of measurement error in clinical trials: time to test new paradigms? J Clin Psychopharmacol 2007; 27: 1-5
43. Keller MB, Klerman GL, Lavori PW, Coryell WH, Endicott J, Taylor J: Long-term outcome of episodes of major depression: clinical and public health significance. JAMA 1984; 252: 788-792
44. Rutherford BR, Mori S, Sneed JR, Pimontel MA, Roose SP: Contribution of spontaneous improvement to placebo response in depression: a meta-analytic review. J Psychiatr Res 2012; 46: 697-702
45. Brody B, Leon AC, Kocsis JH: Antidepressant clinical trials and subject recruitment: just who are symptomatic volunteers? Am J Psychiatry 2011; 168: 1245-1247
46. Kisely S, Scott A, Denney J, Simon G: Duration of untreated symptoms in common mental disorders: association with outcomes. Br J Psychol 2006; 189: 79-80
47. Benedetti F, Arduino C, Costa S, Vighetti S, Tarenzi L, Rainero I, Asteggiano G: Loss of expectation-related mechanisms in Alzheimer's disease makes analgesic therapies less effective. Pain 2006; 121: 133-144
48. Liberman RP: The elusive placebo reactor. Neuropsychopharmacology 1967; 5: 557-566
49. Shapiro AK, Morris LA: The placebo effect in medical and psychological therapies, in Handbook of Psychotherapy and Behavior Change: An Empirical Analysis. Edited by Garfield SL, Bergins AE. New York, Aldine Publishing, 1978, pp 477-536
50. Doongaji DR, Vahia VN, Bharucha MP: On placebos, placebo responses, and placebo responders: a review of psychological, psychopharmacological, and psychophysiological factors, II: psychopharmacological and psychophysiological factors. J Postgrad Med 1978; 24: 147-157
51. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT: Initial severity and antidepressant benefits: a metaanalysis of data submitted to the Food and Drug Administration. PLoS Med 2008; 5:e45
52. Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, Fawcett J: Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 2010; 303: 47-53
53. Glassman AH, Roose SP: Delusional depression: a distinct clinical entity? Arch Gen Psychiatry 1981; 38: 424-427
54. Lespérance F, Frasure-Smith N, Koszycki D, Laliberté MA, van Zyl LT, Baker B, Swenson JR, Ghatavi K, Abramson BL, Dorian P, Guertin MC; CREATE Investigators: Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. JAMA 2007; 297: 367-379
55. Roose SP, Sackeim HA, Krishnan KRR, Pollock BG, Alexopoulos G, Lavretsky H, Katz IR, Hakkarainen H; Old-Old Depression Study Group: Antidepressant pharmacotherapy in the treatment of depression in the very old: a randomized, placebocontrolled trial. Am J Psychiatry 2004; 161: 2050-2059
56. Kirsch I: Are drug and placebo effects in depression additive? Biol Psychiatry 2000; 47: 733-735
57. Kirsch I: Changing Expectations: A Key to Effective Psychotherapy. Pacific Grove, Calif, Brooks/Cole, 1990
58. Muthén B, Brown HC: Estimating drug effects in the presence of placebo response: causal inference using growth mixture modeling. Stat Med 2009; 28: 3363-3385
59. Gueorguieva R, Mallinckrodt C, Krystal JH: Trajectories of depression severity in clinical trials of duloxetine: insights into antidepressant and placebo responses. Arch Gen Psychiatry 2011; 68: 1227-1237
60. Thase ME, Larsen KG, Kennedy SH: Assessing the "true" effect of active antidepressant therapy v placebo in major depressive disorder: use of a mixture model. Br J Psychiatry 2011; 199: 501-507
61. Depression: The Treatment and Management of Depression in Adults (NICE clinical guideline 90). London, National Institute for Health and Clinical Excellence, 2009
62. Lave JR, Frank RG, Schulberg HC, Kamlet MS: Cost-effectiveness of treatments for major depression in primary care practice. Arch Gen Psychiatry 1998; 55: 645-651
63. Domino ME, Foster EM, Vitiello B, Kratochvil CJ, Burns BJ, Silva SG, Reinecke MA, March JS: Relative cost-effectiveness of treatments for adolescent depression: 36-week results from the TADS randomized trial. J Am Acad Child Adolesc Psychiatry 2009; 48: 711-720
64. Barlow DH: Negative effects from psychological treatments: a perspective. Am Psychol 2010; 65: 13-20
65. Tang TZ, DeRubeis RJ, Hollon SD, Amsterdam J, Shelton R, Schalet B: Personality change during depression treatment: a placebo-controlled trial. Arch Gen Psychiatry 2009; 66: 1322-1330
66. Petrovic P, Dietrich T, Fransson P, Andersson J, Carlsson K, Ingvar M: Placebo in emotional processing: induced expectations of anxiety relief activate a generalized modulatory network. Neuron 2005; 46: 957-969
67. Mayberg HS, Silva JA, Brannan SK, Tekell JL, Mahurin RK, McGinnis S, Jerabek PA: The functional neuroanatomy of the placebo effect. Am J Psychiatry 2002; 159: 728-737